

ongoing trials - trial from other registries

## **Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis - - RECRUITING**

**Code:** NCT06429176    **Year:** 2024    **Date:** new

**Author:**

### **Participants**

15 patients 0-17 years with Cystic Fibrosis

### **Interventions**

VX-770 50mg, VX-770 granules, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 granules, VX-445/VX-661/VX-770 fixed-dose combination granules, Ivacaftor 25 mg granules, Kalydeco 59.5 mg granules in sachet, VX-770 75mg, Kaftrio 60 mg/40 mg/80 mg granules in sachet, Kalydeco 50 mg granules in sachet, Kaftrio 75 mg/50 mg/100 mg granules in sachet, VX-445/VX-661/VX-770 granules, Kalydeco 25 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules

### **Outcome measures**

Safety and tolerability assessments as determined by adverse events (AEs), clinical laboratory values, standard 12-lead ECGs, vital signs, and pulse oximetry

<https://clinicaltrials.gov/study/NCT06429176>

### **Keywords**

CFTR Modulators; Genetic Predisposition to Disease; pharmacological\_intervention; placebo; VX-770; VX-661; ivacaftor; Aminophenols; tezacaftor; VX-445; elexacaftor; Trikafta; kaftrio;